Gulfstream Intelligence launches regulatory intelligence and execution platform

Gulfstream Intelligence has announced the launch of a regulatory intelligence and execution platform for pharmaceutical, biotechnology and life science organisations.

Developed by Gulfstream Life Science, the platform was created by regulatory professionals with more than 25 years of experience in the pharmaceutical and biotechnology industry. Gulfstream Intelligence was developed from experience managing global development programmes, health authority interactions, submissions, labelling, regulatory strategy and regulatory team activities.

Gulfstream Intelligence said regulatory teams have access to information and technology, but their work can remain disconnected across systems, documents, spreadsheets, email and presentations. Regulatory intelligence may be maintained in one system, submission plans in another and labelling in separate documents and spreadsheets, while health authority preparation, gap assessments and programme decisions may be managed through email, presentations and individual files.

Gulfstream Intelligence was built to bring these activities together and help regulatory professionals move from finding information to understanding its implications for a programme and determining the actions required.

The platform brings together global regulatory intelligence and policy, global labelling, global regulatory gap assessments, health authority preparation and simulation, submission planning and critical path management, regulatory document intelligence and decision-ready deliverables.

The global regulatory intelligence and policy function enables teams to monitor guidance, legislation, policy changes and health authority developments across global markets and assess how these changes may affect development programmes.

The global labelling function supports the development and lifecycle management of product labelling, including Core Data Sheets and regional labels such as US Prescribing Information, EU Summary of Product Characteristics and Canadian Product Monograph. Teams can compare regional labelling, identify differences, evaluate new safety and efficacy information and maintain consistency between global and local labelling positions.

The global regulatory gap assessment function enables teams to evaluate programmes and regulatory documentation against regional health authority expectations to identify gaps, risks and actions that may be required before an interaction or submission.

The health authority preparation and simulation function supports preparation for meetings and interactions with the FDA, EMA, MHRA, PMDA, Health Canada and other global authorities by identifying likely questions, areas of concern and issues that may require additional justification.

The submission planning and critical path management function enables teams to develop submission plans, timelines, dependencies and deliverables for INDs, BLAs, NDAs, MAAs and other regulatory milestones, while maintaining visibility into activities that may affect submission timelines.

The regulatory document intelligence function reviews regulatory documents to identify inconsistencies, missing information, potential risks and areas requiring attention. The platform also converts regulatory analysis into structured reports, summaries and editable presentations that can be shared with regulatory teams, development teams and leadership.

“The problem is not simply finding regulatory information. It is what happens after the information is found,” said Scott Morvay, Founder of Gulfstream Intelligence. “After more than 25 years working in regulatory affairs, we have seen how quickly important context can become disconnected as information moves between systems, documents and teams. We built Gulfstream around the way regulatory professionals actually work, from understanding an issue to deciding what it means for the program and ultimately doing something about it.”

Gulfstream Intelligence aims to maintain the connection between the regulatory source, professional interpretation of that information, its impact on the development programme, the resulting actions and the final regulatory deliverable.

For larger pharmaceutical organisations, Gulfstream Intelligence provides a way to maintain continuity across programmes, functions, regions and health authorities. Regulatory intelligence, labelling, health authority preparation, submission planning and document review can remain connected rather than being managed as separate workstreams across multiple systems.

For emerging and mid-sized biotechnology companies, Gulfstream provides the same capabilities in one environment. The company said this can support regulatory teams managing broad responsibilities with limited internal resources.

Gulfstream Intelligence was built from the experience of regulatory professionals rather than by adapting a general technology platform to regulatory affairs. The company said this experience informed the platform and how its capabilities work together.

Gulfstream uses artificial intelligence to assist with research, comparison, analysis, planning and drafting, while qualified regulatory professionals remain responsible for reviewing information, interpreting regulatory requirements and making regulatory decisions.

“AI can help us work faster, but regulatory affairs is not simply an information problem,” Morvay said. “Experience matters. Judgment matters. Understanding the development program matters. Gulfstream was built to give regulatory professionals better tools to apply that experience.”

The platform does not replace professional judgment, provide legal advice or independently submit materials to health authorities.

Gulfstream Intelligence is designed to support regulatory teams throughout development, from monitoring changes in the global regulatory environment and assessing programme readiness to preparing for health authority interactions, developing global labelling and planning submissions.

As programmes progress, information generated through these activities can remain connected rather than becoming isolated across separate systems and documents. The platform is designed to provide teams with visibility into what has changed, what it means for their programme, what requires attention and what needs to happen next.

The post Gulfstream Intelligence launches regulatory intelligence and execution platform appeared first on Express Pharma.